Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in the treatment of hematological malignancies, is limited by life-threatening complications: graft versus host disease (GVHD) and infections es...

Full description

Bibliographic Details
Main Authors: Chongsheng Qian, Arnaud Campidelli, Yingying Wang, Huili Cai, Véronique Venard, Hélène Jeulin, Jean Hugues Dalle, Cécile Pochon, Maud D’aveni, Benedicte Bruno, Catherine Paillard, Stéphane Vigouroux, Charlotte Jubert, Patrice Ceballos, Aude Marie-Cardine, Claire Galambrun, Clément Cholle, Isabelle Clerc Urmes, Nadine Petitpain, Marcelo De Carvalho Bittencourt, Véronique Decot, Loïc Reppel, Alexandra Salmon, Laurence Clement, Danièle Bensoussan
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Journal of Hematology & Oncology
Subjects:
Adenovirus-specific T cells
Interferon-γ-based immunomagnetic isolation
Allogeneic stem cell transplantation
Umbilical cord blood transplantation
Third party haploidentical donor
Online Access:http://link.springer.com/article/10.1186/s13045-017-0469-0

Internet

http://link.springer.com/article/10.1186/s13045-017-0469-0

Similar Items